HIGH-VOLUME · FEMALE-LED
etonogestrel Side Effects
etonogestrel (also sold as Nexplanon) is HIGH-VOLUME in this FAERS book #149 of 524 by FAERS report count. Signature opener: FEMALE-LED - 100% of sex-coded reports are female (44,403 F / 82 M).
Data updated 2026-05-15
- 46,939
- FAERS reports
FAERS voluntary reports, 2004 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.
etonogestrel reporting skew - 100% of sex-coded reports are female (44,403 F / 82 M). Volume band HIGH-VOLUME #149 of 524 by FAERS report count; caseload CASELOAD.
High-report extract for etonogestrel (Nexplanon): 46,939 FAERS rows (2004-2025). Top named reactions: PRODUCT QUALITY ISSUE, COMPLICATION ASSOCIATED WITH DEVICE, DEVICE DIFFICULT TO USE. Outcome stamps DEATH-RARE · HOSP-LIGHT · FEMALE-LED. FAERS is voluntary signal detection, not incidence.
Counts from the openFDA FAERS extract (2004–2025). Stamps CASELOAD · DEATH-RARE · HOSP-LIGHT · FEMALE-LED.
PRODUCT QUALITY ISSUE leads 5,554 of 46,939 reports
FEMALE-LED reporters · age peak 18-44
Female-led reporters (100% of sex-coded rows)
Age peak 18-44 (21,245 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death is rare in this extract (94 / 46,939). Co-reported reactions in that thin subset:
| Reaction | Reports |
|---|---|
| DEATH | 24 |
| FOETAL EXPOSURE DURING PREGNANCY | 15 |
| PREMATURE BABY | 10 |
| DEATH NEONATAL | 8 |
| COMPLETED SUICIDE | 7 |
| PULMONARY EMBOLISM | 7 |
| CEREBELLAR HAEMORRHAGE | 6 |
| HEADACHE | 4 |
| MATERNAL DRUGS AFFECTING FOETUS | 4 |
| THROMBOSIS | 4 |
| VAGINAL HAEMORRHAGE | 4 |
| ADVERSE EVENT | 3 |
| ANXIETY | 3 |
| FOETAL DEATH | 3 |
| PREGNANCY WITH CONTRACEPTIVE DEVICE | 3 |
| ABORTION INDUCED | 2 |
| ABORTION SPONTANEOUS | 2 |
| CARDIAC FAILURE | 2 |
| CARDIO-RESPIRATORY ARREST | 2 |
| CEREBROVASCULAR ACCIDENT | 2 |
Reactions in Hospitalization Reports
Hospitalization is lighter here (1,645). Reactions in that subset:
| Reaction | Reports |
|---|---|
| COMPLICATION ASSOCIATED WITH DEVICE | 164 |
| UNINTENDED PREGNANCY | 139 |
| PREGNANCY WITH IMPLANT CONTRACEPTIVE | 129 |
| COMPLICATION OF DEVICE REMOVAL | 113 |
| DEVICE DISLOCATION | 104 |
| NAUSEA | 98 |
| HEADACHE | 94 |
| DEPRESSION | 85 |
| WEIGHT INCREASED | 84 |
| ANXIETY | 79 |
| PAIN | 75 |
| INCORRECT PRODUCT ADMINISTRATION DURATION | 74 |
| VOMITING | 74 |
| PULMONARY EMBOLISM | 72 |
| VAGINAL HAEMORRHAGE | 71 |
| ABDOMINAL PAIN | 65 |
| DIZZINESS | 65 |
| FATIGUE | 64 |
| CHEST PAIN | 58 |
| SURGERY | 58 |
How to read etonogestrel FAERS figures (CASELOAD · DEATH-RARE · HOSP-LIGHT)
FAERS holds 46,939 voluntary reports linked to etonogestrel (Nexplanon), 2004-2025. Death is listed on 94 (0.2%). Hospitalization appears on 1,645 (3.5%). Top co-reported indication: Contraception.
CASELOAD books overweight common drugs and loud reporting cultures; FEMALE-LED is the page opener, not a per-patient risk.
Read with etonogestrel
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-RARE · HOSP-LIGHT stamps.
ABS(total_reports) peer at 47,215 FAERS cases (Δ 276 heavier vs etonogestrel); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-RARE · HOSP-LIGHT · FEMALE-LED.
ABS(total_reports) peer at 47,426 FAERS cases (Δ 487 heavier vs etonogestrel); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's CASELOAD · DEATH-RARE · HOSP-LIGHT · FEMALE-LED.
ABS(total_reports) peer at 47,513 FAERS cases (Δ 574 heavier vs etonogestrel); DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED vs this page's CASELOAD · DEATH-RARE · HOSP-LIGHT · FEMALE-LED.
ABS(total_reports) peer at 47,788 FAERS cases (Δ 849 heavier vs etonogestrel); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-RARE · HOSP-LIGHT · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 61.9 pp vs etonogestrel's DEATH-RARE): CASELOAD · HOSP-MID.
etonogestrel sits in CASELOAD; high report volume tracks exposure and reporting culture more than per-patient risk. Methodology states the de-dup rules.